|
March
Tuesday, Mar 16, 2010 Genentech Submits Supplemental Biologics License Application for ACTEMRA (tocilizumab) for Prevention of Structural Joint Damage and Improvement of Physical Function in Rheumatoid Arthritis Thursday, Mar 11, 2010 Genentech Provides Update on Phase III Study of Avastin in Men With Late Stage Prostate Cancer February Wednesday, Feb 24, 2010 Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer Monday, Feb 22, 2010 Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint Thursday, Feb 18, 2010 FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia January Friday, Jan 15, 2010 FDA Extends Review Period for Tarceva Application for First-line Maintenance Use in Advanced Non-small Cell Lung Cancer Friday, Jan 08, 2010 FDA Approves ACTEMRA® (tocilizumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis See the Archives 
 |
